171 related articles for article (PubMed ID: 36181046)
1. Cutoff values of protein induced by vitamin K absence or antagonist II for diagnosing hepatocellular carcinoma.
Jang TY; Dai CY
Medicine (Baltimore); 2022 Sep; 101(39):e30936. PubMed ID: 36181046
[TBL] [Abstract][Full Text] [Related]
2. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents.
Degasperi E; Perbellini R; D'Ambrosio R; Uceda Renteria SC; Ceriotti F; Perego A; Orsini C; Borghi M; Iavarone M; Bruccoleri M; Rimondi A; De Silvestri A; Sangiovanni A; Lampertico P
Aliment Pharmacol Ther; 2022 Feb; 55(3):350-359. PubMed ID: 34738664
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
[TBL] [Abstract][Full Text] [Related]
5. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis.
Su TH; Peng CY; Chang SH; Tseng TC; Liu CJ; Chen CL; Liu CH; Yang HC; Chen PJ; Kao JH
J Formos Med Assoc; 2022 Mar; 121(3):703-711. PubMed ID: 34452785
[TBL] [Abstract][Full Text] [Related]
6. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein.
Cui R; He J; Zhang F; Wang B; Ding H; Shen H; Li Y; Chen X
Br J Cancer; 2003 Jun; 88(12):1878-82. PubMed ID: 12799630
[TBL] [Abstract][Full Text] [Related]
8. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
[TBL] [Abstract][Full Text] [Related]
9. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.
Wang MD; Sun LY; Qian GJ; Li C; Gu LH; Yao LQ; Diao YK; Pawlik TM; Lau WY; Huang DS; Shen F; Yang T
Int J Surg; 2022 Sep; 105():106843. PubMed ID: 35995351
[TBL] [Abstract][Full Text] [Related]
10. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
[TBL] [Abstract][Full Text] [Related]
11. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
13. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma.
Bhatti ABHH; Naz K; Abbas G; Khan NY; Zia HH; Ahmed IN
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1731-1736. PubMed ID: 34181327
[TBL] [Abstract][Full Text] [Related]
15. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy.
Loglio A; Iavarone M; Facchetti F; Di Paolo D; Perbellini R; Lunghi G; Ceriotti F; Galli C; Sandri MT; Viganò M; Sangiovanni A; Colombo M; Lampertico P
Liver Int; 2020 Aug; 40(8):1987-1996. PubMed ID: 32301212
[TBL] [Abstract][Full Text] [Related]
16. Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients.
Hadi H; Wan Shuaib WMA; Raja Ali RA; Othman H
Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 36013482
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
18. Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma.
Takikawa Y; Suzuki K; Yamazaki K; Goto T; Madarame T; Miura Y; Yoshida T; Kashiwabara T; Sato S
J Gastroenterol Hepatol; 1992; 7(1):1-6. PubMed ID: 1371940
[TBL] [Abstract][Full Text] [Related]
19. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]